PD-1, PD-L1 in BRCA1/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs).

被引：0
|
作者：
Sachdev, Jasgit C.
Arguello, David
Abbott, Brian L.
Reddy, Sandeep K.
机构：
[1] Scottsdale Healthcare, Paradise Valley, AZ USA
[2] Caris Life Sci, Phoenix, AZ USA
[3] Caris Life Sci, Great Falls, MT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e17057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17057
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens
    Alessio Grimaldi
    Ilenia Cammarata
    Carmela Martire
    Chiara Focaccetti
    Silvia Piconese
    Marta Buccilli
    Carmine Mancone
    Federica Buzzacchino
    Julio Rodrigo Giron Berrios
    Nicoletta D’Alessandris
    Silverio Tomao
    Felice Giangaspero
    Marino Paroli
    Rosalba Caccavale
    Gian Paolo Spinelli
    Gabriella Girelli
    Giovanna Peruzzi
    Paola Nisticò
    Sheila Spada
    Mariangela Panetta
    Fabiana Letizia Cecere
    Paolo Visca
    Francesco Facciolo
    Flavia Longo
    Vincenzo Barnaba
    Communications Biology, 3
  • [32] Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
    Dumitru, Adrian
    Dobrica, Elena-Codruta
    Croitoru, Adina
    Cretoiu, Sanda Maria
    Gaspar, Bogdan Severus
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [33] Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
    Chardin, Laure
    Leary, Alexandra
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] SIGNIFICANCE OF PD-1 AND PD-L1 EXPRESSION IN OVARIAN CANCER BIOLOGY
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Giridhar, S.
    Wenzel, S.
    Sprung, S.
    Lax, S.
    Zeimet, A.
    Fiegl, H.
    Marth, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1714 - 1714
  • [35] Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications
    Millis, Sherri Z.
    Abbott, Brian L.
    Baker, Erin H.
    Bender, Ryan
    Swensen, Jeffrey
    Gatalica, Zoran
    Reddy, Sandeep K.
    Rosemurgy, Alexander
    Iannitti, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma
    Li, Hongjie
    Gibson, Joanna
    Jain, Dhanpat
    Finberg, Karin
    Walther, Zenta
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1050 - 1051
  • [37] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
    G E Konecny
    R S Kristeleit
    British Journal of Cancer, 2016, 115 : 1157 - 1173
  • [38] Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
    Kumar, Utpal
    Anthony, Michael Leonard
    Sahai, Rishabh
    Mittal, Ankur
    Durgapal, Prashant
    Kishore, Sanjeev
    JOURNAL OF LABORATORY PHYSICIANS, 2022, 14 (02) : 197 - 201
  • [39] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [40] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
    Konecny, G. E.
    Kristeleit, R. S.
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1157 - 1173
12345